Notably, the compound demonstrates a broad therapeutic index and strong binding affinity to the MEK-RAF complex, offering potential advantages over existing MAPK inhibitors. Preclinical studies ...

While Monday’s trading session was a win for CERo shareholders, the stock’s year-to-date (YTD) performance paints a more complex picture. As of today, CERO is down by a staggering -98.59% YTD, which ...

Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...

To date, the large therapeutic index of sEHIs makes this class of compound particularly attractive in this respect. Because there are numerous accepted treatments for cardiovascular diseases such ...

The Croatian health care strike is set for Monday. Despite this, emergency and urgent medical situations will still be dealt ...

Detailed price information for Biorestorative Therapies Inc (BRTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on November 7, 2024, Maxim Group initiated coverage of Quince Therapeutics (NasdaqGS:QNCX) with a Buy ...

OSE-CYTOMASK is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics that deliver highly active medicines with improved ...

The amount Medicare pays for cancer drugs may be determined by the size of the anticipated treatment population rather than the actual therapeutic value of the drugs, according to researchers.